Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kristina A. Novoselova"'
Autor:
Kristina A. Novoselova, Irina L. Popova, Ludmila A. Ryadinskaya, Maria A. Teplyakova, Maria Ezhova, L Yu Vladimirova, L. K. Strakhova, Valeriya S Myagkova, Natalya A Abramova, Natalya Mikhailovna Tikhanovskaya, Aza A. Lyanova
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 174-180 (2020)
Patients with brain metastases of HER2-positive breast cancer (BC) is a special group of patients who are difficult to treat and have a short life expectancy. The possibilities of whole brain radiotherapy, stereotactic radiosurgery and surgery in suc
Autor:
Aza A. Lyanova, L Yu Vladimirova, Kristina A. Novoselova, Irina L. Popova, Natalya A Abramova, Valeriya S Myagkova, Maria A. Teplyakova, A. E. Storozhakova, L. K. Strakhova, Ludmila A. Ryadinskaya, Elena A. Kalabanova, Natalya Mikhailovna Tikhanovskaya, Elena P. Ulianova
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 182-189 (2020)
Introduction:Squamous cell carcinoma of the oral cavity is one of the most common head and neck cancers with an aggressive course and high mortality rates.The aimof the study was to determine the EGFR expression levels in tumor tissues in patients wi
Autor:
Oksana V. Katelnitskaya, Irina S. Tishchenko, Elena A. Shevyakova, Irina B. Lysenko, Tatiana A. Zykova, Anna V. Tishina, Aza A. Lyanova, Lyudmila A. Ryadinskaya, Sergey N. Kabanov, Elena A. Kalabanova, Natalya Mikhailovna Tikhanovskaya, Lyubov Vladimirova, Andrey A. Maslov, Natalia A. Abramova, Kristina A. Novoselova, Anna E. Storozhakova, Irina L. Popova
Publikováno v:
I.P. Pavlov Russian Medical Biological Herald. 28:44-56
Aim. To study the prevalence of carriage of polymorphic allele variants of genes of blood coagulation factors in oncological patients. Materials and Methods. 213 Patients with morphologically confirmed oncological diseases were examined. Samples of g
Autor:
N. S. Besova, Elena Artamonova, Kristina A. Novoselova, Vladimir Moiseyenko, Liubov Yu Vladimirova, Natalia Trenina, Margarita Suetina, Sergei Tjulandin, Ilya Tsimafeyeu, Vyacheslav Kurakin, Galina Statsenko, Mikhail Byakhov, Alina Kashanova, Ekaterina Obarevich, Natalia А. Abramova, Anastasia Mochalova
Publikováno v:
Cancer Research. 81:CT113-CT113
Fibroblast growth factor receptor 2 (FGFR2) is associated with an unfavorable prognosis in patients with gastric cancer. Acquired mutations in FGFR2 develop resistance to multikinase inhibitors. Besides, resistance to monoclonal antibodies depends on
Autor:
Irina L. Popova, Liubov Yu Vladimirova, Anna E. Storozhakova, Aza A. Agieva, Faina V. Alieva, Natalia A. Abramova, Elena S. Bondarenko, Kristina A. Novoselova, Natalia M. Tikhanovskaya, Sergey N. Kabanov, Inna Arnoldovna Novikova, Elena Yu. Zlatnik, Aleksandr B. Sagakyants, Yuriy N. Lazutin, Maria A. Teplyakova, Oleg I. Kit, Elena A. Kalabanova, Ludmila A. Ryadinskaya, Anna V. Tishina
Publikováno v:
Journal of Clinical Oncology. 39:e21035-e21035
e21035 Background: Immunotherapy with PD-1/PD-L1 check-point inhibitors (CPI) is a new trend in oncology. Their effect significantly depends on the patients` immune status. The aim of the study was to search the immunologic parameters of lung cancer
Autor:
Irina L. Popova, Faina V. Alieva, Aza A. Agieva, Oleg N. Burov, Yaroslav S. Enin, Natalia M. Tikhanovskaya, Marina M. Sergeeva, Valeriya S Myagkova, Liubov Yu Vladimirova, Ludmila A. Ryadinskaya, Natalia A. Abramova, Maria A. Teplyakova, Elena Yu. Zlatnik, Kristina A. Novoselova
Publikováno v:
Journal of Clinical Oncology. 39:e15063-e15063
e15063 Background: The study of the possible antitumor activity of secondary plant metabolites either in the form of individual agents or in combination with clinically used drugs is considered as a promising direction in the therapy of malignant tum
Autor:
Oleg I. Kit, Aza A. Agieva, Valeria S. Karnaukhova, Tatiana A. Zykova, Irina L. Popova, Maria A. Teplyakova, Natalia A. Abramova, Natalia M. Tikhanovskaya, Oksana V. Katelnitskaya, Sergey N. Kabanov, Anna V. Tishina, Ludmila A. Ryadinskaya, Anna E. Storozhakova, Elena A. Kalabanova, Andrey A. Maslov, Elena A. Shevyakova, Irina S. Tishchenko, Kristina A. Novoselova, Liubov Yu Vladimirova
Publikováno v:
Journal of Clinical Oncology. 39:e16011-e16011
e16011 Background: The purpose of the study was to analyze the rates of polymorphic allelic variants of genes of the hemostasis system and methionin exchange in patients with gastrointestinal cancers (GICs). Methods: The study included 69 patients wi
Autor:
A.S. Ratieva, Natalia M. Tikhanovskaya, Aza A. Agieva, Valeriya S Myagkova, Ekaterina P. Omelchuk, Irina L. Popova, Ludmila A. Ryadinskaya, Natalya N. Timoshkina, Faina V. Alieva, Dmitry Yu. Gvaldin, Liubov Yu Vladimirova, Marina M. Sergeeva, Kristina A. Novoselova, Larisa N. Vashchenko, Natalia A. Abramova, Maria A. Teplyakova
Publikováno v:
Journal of Clinical Oncology. 39:12005-12005
12005 Background: Numerous pharmacogenetic studies have led to the identification of genetic polymorphisms associated not only with the development of cardiovascular disease, but also increase the risk of complications due to the use of anthracycline
Autor:
Aleksandr E. Lisutin, Irina L. Popova, Maria О. Ezhova, Natalia А. Abramova, Elena А. Sycheva, Tatiana P. Protasova, Kristina А. Novoselova, Aza А. Lyanova, Lyudmila А. Ryadinskaya, Stella M. Babieva, Yulia Yu. Arapova, Anna E. Storozhakova, Natalia M. Tikhanovskaya, Alla I. Shikhlyarova, Yuliana S. Shatova, Viktoria V. Pozdnyakova, Lyubov Vladimirova, Irina R. Dashkova
Publikováno v:
Cardiometry, Iss 13 (2018)
Aims The aim is to study the action and effects of antitumor polychemotherapy (PCT) with Anthracyclines on the cardiovascular system performance in primary oncological patients with breast cancer (BC). Materials and methods The study involved 21 fema
Autor:
Aza A. Agieva, T A Snezhko, L Yu Vladimirova, Oleg I. Kit, Natalia Yu. Samaneva, Irina L. Popova, Sergey N. Kabanov, A. E. Storozhakova, Elena A. Kalabanova, N. M Tkhanovskaya, Kristina A. Novoselova, Nataliya Abramova
Publikováno v:
Russian Journal of Oncology. 21:66-71
Clinical data on the efficacy and safety of cetuximab and panitumumab in 87 patients in the 1-4 lines of drug therapy for metastatic colorectal cancer (mCRC) with wild-type RAS with and without surgical removal of metastases were analyzed. Anti-EGFR